ContraFect Corporation
(Nasdaq:CFRX), a clinical-stage biotechnology
company focused on the discovery and development of direct lytic
agents (DLAs), including Lysins and Amurin peptides, as new medical
modalities for the treatment of life-threatening,
antibiotic-resistant infections, today announced that it has been
granted two oral presentations at the 30th European Congress of
Clinical Microbiology and Infectious Diseases (ECCMID) to be held
from April 18-21, 2020, in Paris, France.
The oral presentations include new data
demonstrating the ability of the Company’s lead compound,
exebacase, to resensitize methicillin-resistant Staph aureus (MRSA)
to methicillin-derivatives in an animal model of infective
endocarditis. Exebacase is currently being studied in the Pivotal
Phase 3 DISRUPT (Direct Lysis of Staph aureus Resistant Pathogen
Trial) study of exebacase in patients with Staph aureus bacteremia,
including right-sided endocarditis.
A second oral presentation will cover new data
demonstrating the potent activity of the Company’s lead Amurin
peptides candidates against carbapenem-resistant
Enterobacteriaciae, Acinetobacter baumannii, and Pseudomonas
aeruginosa, including extensively resistant strain that are also
resistant to Colistin. These in vitro data strongly support the
further preclinical development of these new modality agents, which
demonstrate potent activity against some of the most extensively
resistant human pathogenic strains of Gram-negative bacteria.
“In December of last year, we initiated our
Phase 3 superiority trial of exebacase. This single, pivotal study
aims to further confirm the data from Phase 2 which showed that
treatment with exebacase was associated with a 43% higher rate of
clinical response, a 21 percentage point reduction in 30-day
all-cause mortality, a four day reduction in length of hospital
stay and meaningful reductions in hospital readmission rates in the
prespecified MRSA subgroup. We are pleased to have demonstrated
proof of concept for direct lytic agents in the Phase 2 study,
which provides us with increased confidence as we bring entirely
new classes of molecules rapidly to the clinic,” said Cara Cassino,
M.D., Chief Medical Officer and Executive Vice President of
Research and Development at ContraFect.
Oral Presentations:
Presentation
Title: First report of the discovery
of amurin peptides: direct lytic agents with broad activity against
carbapenem-resistant Enterobacteriaciae, Acinetobacter, and
Pseudomonas, including colistin-resistant strains Session
Title: New insights on the therapeutic potential of
bacteriophages
Presentation Title: Exebacase
resensitises methicillin-resistant Staphylococcus aureus to
oxacillin in a rabbit model of infective
endocarditisSession Title: Drug combinations
against multi-resistant bacteria
Presentation details will be released ahead of
the conference. The abstracts can be accessed through
the ECCMID website.
About ContraFect:
ContraFect is a biotechnology company focused on
discovering and developing differentiated biologic therapies for
life-threatening, drug-resistant infectious diseases, particularly
those treated in hospital settings. An estimated 700,000 deaths
worldwide each year are attributed to antimicrobial-resistant
infections. We intend to address life threatening infections using
our therapeutic product candidates from our platform of DLAs, which
include lysins and amurin peptides. Lysins are a new class of DLAs
which are recombinantly produced antimicrobial proteins with a
novel mechanism of action associated with the rapid killing of
target bacteria, eradication of biofilms and synergy with
conventional antibiotics. Amurin peptides are a new class of DLAs,
which exhibit broad-spectrum activity against a wide range of
antibiotic-resistant Gram-negative pathogens, including Pseudomonas
aeruginosa (P. aeruginosa), Acinetobacter baumannii, and
Enterobacter species. We believe that the properties of our lysins
and amurin peptides will make them suitable for targeting
antibiotic-resistant organisms, such as methicillin-resistant Staph
aureus (MRSA) and P. aeruginosa, which can cause serious infections
such as bacteremia, pneumonia and osteomyelitis. We have completed
a Phase 2 clinical trial for the treatment of Staph aureus
bacteremia, including endocarditis, with our lead lysin candidate,
exebacase, which is the first lysin to enter clinical studies in
the U.S.
Follow ContraFect on Twitter @ContraFectCorp and
LinkedIn.
Forward-Looking
Statements:
This press release contains, and our officers
and representatives may make from time to time, “forward-looking
statements” within the meaning of the U.S. federal securities
laws. Forward-looking statements can be identified by words
such as “projects,” “may,” “will,” “could,” “would,” “should,”
“believes,” “expects,” “anticipates,” “estimates,” “intends,”
“plans,” “potential,” “promise” or similar references to future
periods. Examples of forward-looking statements in this release
include, without limitation, statements regarding ContraFect’s
ability to discover and develop DLAs as new medical modalities for
the treatment of life-threatening, antibiotic-resistant infections,
statements made regarding the oral presentations, statements made
by ContraFect’s Chief Medical Officer, ContraFect’s ability to
address life threatening infections using its DLA platform,
whether lysins are a new class of DLAs which are
recombinantly produced, antimicrobial proteins with a novel
mechanism of action associated with the rapid killing of target
bacteria, eradication of biofilms and synergy with conventional
antibiotics, whether amurins exhibit broad-spectrum activity
against a wide range of antibiotic-resistant Gram-negative
pathogens and whether the properties of ContraFect’s lysins
and amurins will make them suitable for targeting
antibiotic-resistant organisms, such as Staph aureus and P.
aeruginosa. Forward-looking statements are statements that are not
historical facts, nor assurances of future performance. Instead,
they are based on ContraFect’s current beliefs, expectations and
assumptions regarding the future of its business, future plans,
strategies, projections, anticipated events and trends, the economy
and other future conditions. Because forward-looking statements
relate to the future, they are subject to inherent risks,
uncertainties and changes in circumstances that are difficult to
predict and many of which are beyond ContraFect’s control,
including those detailed under the caption “Risk Factors” in
ContraFect's filings with the Securities and Exchange
Commission. Actual results may differ from those set forth in
the forward-looking statements. Important factors that could cause
actual results to differ include, among others, our ability to
develop treatments for drug-resistant infectious diseases. Any
forward-looking statement made by ContraFect in this press release
is based only on information currently available and speaks only as
of the date on which it is made. Except as required by applicable
law, ContraFect expressly disclaims any obligations to publicly
update any forward-looking statements, whether written or oral,
that may be made from time to time, whether as a result of new
information, future developments or otherwise.
Investor Relations Contacts:
Michael MessingerContraFect CorporationTel: 914-207-2300Email:
mmessinger@contrafect.com
Lauren StivalStern Investor RelationsTel: 212-362-1200Email:
lauren.stival@sternir.com
ContraFect (NASDAQ:CFRX)
Historical Stock Chart
From Mar 2024 to Apr 2024
ContraFect (NASDAQ:CFRX)
Historical Stock Chart
From Apr 2023 to Apr 2024